News28 Mar 2024 07:54
28 March 2024
ASX Code: MXC
LSE Code: MXC
Refinancing of Convertible Securities Agreement
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’) wishes to advise that it has executed a
Deed of Variation with Mercer Street Global Opportunity Fund, LLC (Mercer) in respect of the convertible
securities agreement entered into between the Company and Mercer in 2020. This includes the
refinancing of 500,000 convertible notes from the 2020 convertible note facility (Notes) which totals
$2,100,000. A commercial agreement has been reached by which the minimum conversion price of the
Notes has been reduced from not less than $10.00 to not less than $0.35. Further details in respect of
the variation to the Notes are set out below.
Variation to 2020 Convertible Securities Agreement
As announced on 10 September 2020, the Company entered into an agreement with Mercer (2020
Agreement), whereby Mercer conditionally agreed to provide the Company with up to $15 million in
funding, via subscriptions for convertible notes in the Company with a face value of AUD$1.00 each.
As at the date of this announcement 2,100,000 convertible notes pursuant to the terms of the 2020
Agreement remain on issue.
The Company and Mercer have agreed to amend the minimum conversion price of 500,000 Notes under
the 2020 Agreement (which had amendments approved at a meeting of Shareholders1
) from “not less
than $10.00” (post consolidation) to “not less than $0.35” (post consolidation). The issue of any
conversion shares as a result of the amendment of the minimum conversion price will be made under
the Company’s existing placement capacity under Listing Rule 7.1.
The Company intends to reach additional agreements with Mercer to amend the terms of the remaining
2020 convertible note facility and the 2022 convertible note facility2
.
—Ends—
MXC.L Share Price (MXC)
MXC Share
MXC Share
MXC Share
MXC Share
MXC
MXC Share
MXC Broker
MXC Directors
MXC Financial
MXC
MXC Short
MXC
